Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Harvard Medical School, Boston, MA.
Am Soc Clin Oncol Educ Book. 2023 Jun;43:e397912. doi: 10.1200/EDBK_397912.
Chimeric antigen receptor (CAR) T-cells are a cellular immunotherapy with remarkable efficacy in treating multiple hematologic malignancies but they are associated with extremely high prices that are, for many countries, prohibitively expensive. As their use increases both for hematologic malignancies and other indications, and large numbers of new cellular therapies are developed, novel approaches will be needed both to reduce the cost of therapy, and to pay for them. We review the many factors that lead to the high cost of CAR T-cells and offer proposals for reform.
嵌合抗原受体 (CAR) T 细胞是一种细胞免疫疗法，在治疗多种血液恶性肿瘤方面具有显著疗效，但价格极高，许多国家都难以承受。随着 CAR T 细胞在血液恶性肿瘤和其他适应证中的应用不断增加，以及大量新的细胞疗法的开发，不仅需要新的方法来降低治疗成本，还需要为其支付费用。我们回顾了导致 CAR T 细胞高成本的诸多因素，并提出了改革建议。
